Skip to main content
Clinical Trials/TCTR20230713010
TCTR20230713010
Recruiting
Not Applicable

The Characteristic of Retinal Nerve Fiber Layer Thickness in Advance and End-stage Glaucoma using Spectral Domain Optical Coherence Tomography

Faculty of Medicine Siriraj Hospital, Mahidol University0 sites80 target enrollmentJuly 13, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
This research aims to study structural changes (retinal nerve fiber layer) in patients with advance and end-stage glaucoma, by compare the characteristic of retinal nerve fiber layer thickness between advance and end-stage glaucoma using spectral domain optical coherence tomography, to find the prevention the progression of the disease from advance to end-stage glaucoma.
Sponsor
Faculty of Medicine Siriraj Hospital, Mahidol University
Enrollment
80
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 13, 2023
End Date
May 31, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Glaucoma patients older than 18 years.
  • 2\. The patient was diagnosed with glaucoma.
  • 3\. Advanced glaucoma patients include glaucoma patients with visual field effect, less than 10 degree and visual acuity more than 6/60 from automated perimetry test (Automated perimetry results must have the reliability index according to fixation loss, false negative and false positive less than 30%.
  • 4\. Patients with end\-stage glaucoma include glaucoma patients with visual acuity less than light perception. Automated perimetry is not possible in a patient with end\-stage glaucoma group because low vision. Therefore, the patient was definitely end\-stage glaucoma without other affecting the optic nerve (optic nerve head and retinal nerve fiber layer thickness). This group, patients had only one eye of end\-stage glaucoma, and the other side must have visual acuity more than 6/60 to be able to read and sign the inform consent form by themself.
  • 5\. The patient had a visual field examination (only advance glaucoma group) and spectral domain optical coherence tomography with a time difference, not longer than 6 months.

Exclusion Criteria

  • 1\. Glaucoma patients who can not cooperate with automated perimetry test (only advanced glaucoma group) and Spectral domain optical coherence tomography test (open eyelid, look straight, remain still for about 1 minute and no vision required)
  • 2\. Spectral domain optical coherence tomography results are unreliable, signal strength less than 6\.
  • 3\. Patients with retinal disease that affects retinal nerve fiber layer thickness
  • 4\. Patients with disease non\-glaucomatous optic neuropathy
  • 5\. Patients with secondary glaucoma
  • 6\. Patients with other diseases that is not glaucoma received therapeutic drugs that affect the optic nerve and retinal nerve fiber layer thickness, such as chloroquine.
  • 7\. Patients with ocular inflammation or uveitis.
  • 8\. Patients who underwent intraocular surgery within 3 months prior to examination by Spectral domain optical coherence tomography and Automated perimetry.
  • 9\. Cannot read and sign the inform consent form by themself. the other side must have visual acuity less than 6/60\.

Outcomes

Primary Outcomes

Not specified

Similar Trials